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Abstract
The transmembrane protein, c- Met, is thought to be overexpressed and activated in 
colorectal cancer (CRC). This study explored its potential as a diagnostic tissue bio-
marker for CRC in a large human CRC tissue collection obtained from a randomized 
clinical trial.
Tissue microarrays of matched normal colorectal epithelium and primary cancer 
were prepared from specimens obtained from 280 patients recruited to the MRC 
CLASICC trial (ISRCTN 74883561) and interrogated using immunohistochemis-
try for c- Met expression. The distribution and intensity of immunopositivity was 
graded using a validated, semi- quantifiable score, and differences in median scores 
analysed using the Wilcoxon signed- rank test. A receiver operating characteristic 
(ROC) curve was plotted to measure the diagnostic accuracy of c- Met as a bio-
marker in CRC.
Epithelial cell membrane expression of c- Met differed significantly between CRC 
and normal colorectal tissue: median 12.00 (Interquartile range (IQR) 6- 15) versus 
median 6.00 (IQR 2.70- 12.00) respectively (P = <.0001). ROC- AUC analysis of c- 
Met expression yielded a CRC diagnostic probability of 0.66 (95% CI: 0.61 to 0.70; 
P < .0001). A score of ≥14.50 showed high specificity at 85.32% (95% CI 80.33%- 
89.45%) but sensitivity of only 30.92% (CI 25.37%- 36.90%).
Thus c- Met is consistently overexpressed in human CRC as compared to normal 
colorectal epithelium tissue. c- Met expression may have a role in diagnosis and prog-
nostication if combined with other biomarkers.
K E Y W O R D S
biomarker, c- Met, colorectal cancer, immunohistochemistry
   | 173ARMSTRONG eT Al.
1 |  INTRODUCTION
Colorectal cancer (CRC) is the fourth most common cancer 
in the UK, with around 42,000 newly diagnosed cases each 
year.1 The majority of CRC is associated with mutations in 
oncogenes, tumour suppressor genes and DNA mismatch 
repair genes. These mutations initiate and propagate the 
adenoma- carcinoma sequence towards the development of 
malignant disease in the majority of cases.2 Patient survival 
is strongly influenced by tumour stage at the time of initial 
diagnosis, with 1- year overall survival rates of 98% vs. 40% 
for American Joint Committee on Cancer stage 1 and stage 4 
respectively.3
Biomarkers are routinely used in clinical practice 
for diagnosis, to guide prognostication and to predict 
response to treatment. Expression of the oncofoetal an-
tigen, carcinoembryonic antigen (CEA), is assessed as 
a blood serum biomarker of CRC and is routinely used 
to guide postoperative surveillance for recurrent dis-
ease.4,5 The absence of activating Kirsten rat sarcoma 
viral oncogene (KRAS) and neuroblastoma RAS viral 
oncogene homolog (NRAS) mutations is confirmed prior 
to commencing anti- EGFR (anti- epidermal growth fac-
tor receptor) monoclonal antibody in advanced CRC 6- 9 
due to the negative predictive effect of these mutation; 
however, most wild- type patients still show no signif-
icant response to these agents. High expression of the 
ligands of EGFR, epiregulin (EREG) and amphiregulin 
(AREG) at the RNA level was deemed highly predic-
tive of therapeutic benefit with the anti- EGFR agent 
panitumumab in KRAS/NRAS wild- type metastatic 
CRC in the PICCOLO trial (International Standard 
Randomised Controlled Trial Number (ISRCTN): 
93248876)7,10; however, routine assessment of these or 
other predictive tissue biomarkers is not routinely per-
formed in CRC.
The receptor tyrosine kinase, mesenchymal- epithelial 
transition factor (c- Met), is a transmembrane protein and 
key mediator of many cellular processes. The expression 
of c- Met receptor is primarily localized to epithelial tis-
sues and is activated by the ligand hepatocyte growth 
factor (HGF). Under normal conditions, the formation of 
this receptor- ligand complex is vital for many processes, 
including embryogenesis, tissue regeneration, disruption 
of cell- to- cell adhesion, promotion of morphogenesis and 
differentiation.11- 13 The expression of c- Met has been 
found to be upregulated in many malignancies, including 
non- small- cell lung cancer,14 hepatocellular carcinoma15 
and CRC.16 Increased expression of c- Met protein in 
cancer can be stimulated by physiological hypoxia. This 
adaptive response gives malignant cells a survival ben-
efit within hypoxic tumour microenvironments.17 In re-
cent years, there has been increasing interest in c- Met as a 
diagnostic and prognostic biomarker, with several studies 
suggesting that over expression is linked to poorer sur-
vival in CRC.18
Our study is the first of its kind to investigate the potential 
for c- Met to serve as a diagnostic biomarker for CRC by eval-
uating its expression in a tissue obtained from a randomized 
controlled trial of resected CRC.
2 |  MATERIALS AND METHODS
2.1 | Trial cohort and ethical approval
The Medical Research Council (MRC) CLASICC trial 
(ISRCTN 74883561)19,20 recruited patients with potentially 
curable CRC to either laparoscopic or open resection. Consent 
was obtained from participating patients for residual sam-
ples of normal colorectal epithelium and cancer to be stored 
for future research. Ethical approval for use of tissue from 
the MRC CLASICC trial was obtained from the National 
Research Ethics Service (London- Dulwich Committee), ref-
erence 12/LO/1327 in 2012. Formalin fixed paraffin embed-
ded (FFPE) tissue samples from a representative subgroup of 
280 patients were incorporated into seven anonymized tissue 
microarrays (TMA). Three tumour cores and three matched 
normal mucosa cores (each 0.6mm diameter) from the most 
representative area of the archived resection block were in-
corporated into the TMA.5 Control tissue samples of archival 
placenta, ovary, prostate, kidney, epididymis, liver, gallblad-
der, stomach, oesophagus, pancreas, small bowel, lung and 
muscle were incorporated into the TMA margins for com-
parative and orientation purposes.
2.2 | Immunohistochemical detection of 
c- met protein in tissue samples
Sections were prepared from the TMA blocks onto 
SuperFrost Plus Adhesion glass slides (Thermo Fisher 
Scientific, Altrincham, UK) at 5μm thickness. These were de- 
paraffinized in xylene and rehydrated in decreasing concen-
tration gradients of ethanol. Heat- induced antigen retrieval 
was performed by placing the slides into citric acid buffer 
solution, adjusted to pH 6.2, and microwaved for 10 minutes 
at 900W. Slides were then incubated with an anti- c- Met mon-
oclonal antibody (1:250, Recombinant anti- c- Met antibody 
[EP1454Y], Abcam PLC, Cambridge, UK) for one hour at 
room temperature. Following incubation with the primary 
anti- c- Met antibody, slides were incubated with SignalStain® 
Boost IHC Detection Reagent (HRP, Rabbit; Cell Signalling 
Technology Inc, Leiden, Netherlands) for 30 minutes in a hu-
midified chamber. The SignalStain® 3,3'- diaminobenzidine 
(DAB) Substrate Kit (Cell Signalling Technology Inc, 
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Leiden, The Netherlands) was used, and the chromogen solu-
tion applied for 10 minutes for antibody visualization. In be-
tween each incubation step, the slides were washed in a dilute 
solution of tris- buffered saline solution. Slides were counter-
stained with Mayer's Haematoxylin solution (Sigma- Aldrich 
Scientific Inc, Gillingham, UK), dehydrated and mounted on 
glass cover slips.
2.3 | Imaging
Whole slide images were produced at x40 magnification 
with the Leica BioSystems Aperio AT2 whole slide scanner 
(Leica Microsystems Ltd, Milton Keynes, UK). Slide images 
were viewed at x40 magnification and assessed using Aperio 
ImageScope v12.4.0.5043 (Leica BioSystems Pathology 
Imaging Ltd, Milton Keynes, UK).
2.4 | Scoring c- Met expression
The distribution and intensity of c- Met protein expression was 
assessed by a trained research fellow, using a previously vali-
dated scale.5,21- 23 c- Met protein immunopositivity in epithelial 
cell membranes from each tissue core was scored. The intensity 
of the chromogenic reaction was quantified with a numerical 
scale between 0 and 3 (0 = no detectable expression, 1 = mild 
expression, 2 = moderate expression and 3 = strong expres-
sion). The distribution of membranous c- Met immunopositiv-
ity was determined by calculating the percentage of tumour 
or normal epithelial cells deemed positive as a percentage of 
all of the tumour/normal epithelial cells in the core total area. 
For tumour cores, non- cancerous tissue was excluded from the 
analysis. (The distribution was graded 0 = <5%, 1 = 5%- 20%, 
2 = 21%- 40%, 3 = 41%- 60%, 4 = 61%- 80%, 5 = 81%- 100%.) 
The intensity and distribution scores generated were multiplied 
to provide a compound c- Met expression score. Cores with 
insufficient tumour or normal epithelial tissue for assessment 
were not included. Control TMA slides were prepared to ex-
clude fixation dependent observations. In total, 263 tumour 
and 253 normal epithelium core triplicates (or pairs if a single 
core not assessable) were suitable for analysis and 242 matched 
tumour- normal tissue paired samples (86.43% of pairs) were 
included in the final analysis.
The scoring criteria were appraised and approved by all 
authors in a consensus meeting prior to initiating the scor-
ing process. Representative examples of c- Met expression at 
each distribution score 0 to 5 and intensity score 0 to 3 were 
approved by the group and available for reference throughout 
the scoring process. Independent verification was provided 
by a second research fellow with appropriate experience of 
IHC scoring beforehand. Ten per cent of the 242 matched 
tumour- normal paired samples were selected at random 
and presented for secondary verification. Where discrep-
ancy arose between the reviewers a consensus decision was 
reached.
2.5 | Statistical analysis
Microsoft Excel and Graphpad Prism 7 (GraphPad V7.04 
Software, Inc, California, USA) were used for all data 
handling and statistical analyses. Wilcoxon matched- pairs 
signed- rank test was used to compare the median rank dif-
ference in scores between the matched (tumour and nor-
mal tissue) TMA samples. The interquartile range (IQR) 
and two- tailed P value are reported. A statistical signifi-
cance threshold of P  =  <.05 was applied. The Wilcoxon 
matched- pairs test estimate of the 95% confidence inter-
val (95% C.I) of the median difference bound by the IQR 
were calculated. This method used binominal probabilities 
to predict the 95% C.I around the median and is therefore 
asymmetrical around the median value provided.24 To ac-
count for uncertainty in the data caused by missing core 
sample pairs, a sensitivity analysis assuming the highest c- 
Met expression (compound score 15) for all missing data 
fields was performed.
A receiver operating characteristic curve (ROC curve) 
was plotted to determine the diagnostic accuracy of c- Met 
protein expression in CRC. The sensitivity of c- Met for 
the detection of CRC (true positive rate) was plotted as 
a function of the specificity (true negative rate) and used 
to calculate varying decision cut- off thresholds. The area 
under the curve (AUC) was calculated to numerically 
quantify the diagnostic accuracy of various c- Met expres-
sion scores in discriminating normal epithelial from can-
cerous tissue.
3 |  RESULTS
3.1 | Population demographics of the 
CLASICC trial participants
The key demographic and clinicopathological characteristics 
of the 280 patient cohort from the CLASICC trial are shown 
inTable 1.5,19,20 Entire sample triplicates of seventeen tumour 
(6.07%) and 27 (9.64%) normal epithelial tissue cores were 
ungradable.
3.2 | c- Met expression
The normality test was applied and confirmed the popula-
tions were not sampled from a normal distribution, and a 
non- parametric test was required: skewness −0.61 and 0.29 
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and kurtosis −1.1 and −1.3 for tumour and normal tissue re-
spectively (P <.0001).
Variable c- Met immunopositivity was observed across 
the tissue core population. CRC demonstrated more frequent 
strong c- Met expression as compared to normal epithelial mu-
cosa. High expression was defined as an overall c- Met expres-
sion intensity score of 15 and was found in 30.80% (81/263) of 
CRC samples as compared to 12.25% (31/253) in normal tis-
sue samples (P <.0001). No detectable c- Met expression with 
a composite c- Met expression score of 0 was found in 7.90% 
(20/253) of normal colorectal tissue samples versus 3.42% 
(9/263) in matched tumours (P <.0001). Representative ex-
amples of c- Met expression are shown in Figure 1.
The median tissue c- Met IHC expression scores were 12.0 
for tumour (IQR 6.0 to 15.0) and 6.0 for normal epithelium 
(IQR 2.7 to 12.0) P =<0.0001 (Table 2). Wilcoxon matched- 
pairs test showed a significant difference between the median 
expression scores of malignant and normal colorectal tissue, 
median difference 2.33 (IQR −0.25 to 7.7) and with a differ-
ence of sum of signed- rank W score of 15 397 (P <.0001) 
(n = 242 pairs).
3.3 | Accuracy of c- Met as a colorectal 
cancer diagnostic biomarker
The receiver operating characteristics (ROC) curve and the 
area under curve (AUC) of the sensitivity and specificity of 
c- Met expression at various thresholds are shown in Figure 2. 
The ROC- AUC score yielded an overall diagnostic accuracy 
predictive probability score of 0.66 (95% CI: 0.61 to 0.70; 
P = <.0001).
A total expression score of ≥ 14.50 yielded a high speci-
ficity of 85.32% (C.I 80.33% to 89.45%); however, there was 
a significant trade- off with sensitivity of 30.92% (C.I 25.37% 
to 36.90%) and a likelihood ratio of 2.11. A combined score 
of the total sensitivity and specificity from each cut- off gen-
erated by the ROC curve was calculated. An overall c- Met 
expression score cut- off of ≥ 11.58, yielded the greatest com-
bined true positive and true negative rate with a sensitivity of 
55.73% (95% CI 49.48% to 61.84%) and specificity of 71.83% 
(95% CI 65.84% to 77.29%), likelihood ratio 1.98. The highest 
likelihood ratio of 2.29 was observed with a c- Met expres-
sion score of ≥ 13.17: sensitivity 40.84% (95% CI 34.83% to 
47.06%) and specificity 82.14% (95% CI 76.85% to 86.67%).
T A B L E  1  Key clinical and pathological features of CLASICC 
TMA patient cohort. Adapted from.5,23,24 Staging performed according 
to TNM version 5
Characteristic
Number of cases 
(%)N = 280










Note: The utility of c- Met as a diagnostic tissue biomarker in primary colorectal 
cancer.
F I G U R E  1  A, example of c- Met expression in matched participant normal epithelium and colorectal cancer tissue TMA at each scoring 
threshold. Whole core imaged at x13 magnification for illustrative purposes. B, Example of high c- Met expression in normal and colorectal cancer 
tissue at x13 and x40 magnification
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3.4 | Sensitivity analysis
The sensitivity analysis assumed the highest level of c- Met 
expression for all missing data (compound score 15). This 
confirmed a significant difference in median score between 
the matched tissue samples, 12.30 for tumour (IQR 7.58- 
15.00; P = <.0001) and 10.00 for normal epithelium (IQR 
6.00- 13.30; P  =  <.0001). Similarly, the ROC- AUC analy-
sis showed an AUC value of 0.60 (95% CI 0.55 to 0.64; 
P  =  <.0001). However, intense c- Met immunopositivity 
(expression score ≥14.50) yielded a slightly lower CRC pre-
dictive value specificity of 78.47% (95% CI 73.12% to 83.19%) 
and sensitivity of 33.94% (95% CI 28.35% to 39.88%) with a 
likelihood ratio 1.19.
4 |  DISCUSSION
Oncogenic activation of the transmembrane protein, c- Met, 
has been reported to induce multiple intracellular changes 
leading to the development and progression of cancers.23,25- 27 
Overexpression of c- Met has been reported in several gas-
trointestinal malignancies, including CRC.24 Previous small 
studies have identified the overexpression of c- Met in meta-
static CRC as a predictor of poor overall and progression- free 
survival.23,26,27 We quantified the expression of c- Met pro-
tein in matched tumour and normal epithelial tissue samples 
from participants of the MRC CLASICC trial. Our study is 
unique in its utilization of tissue from a multi- centre RCT 
study cohort to examine a novel biomarker, both in its size 
and representation of the CRC patient population in the UK.
We adopted a previously validated scoring system5,21- 23 
in this study. Tumour samples had a significantly increased 
median c- Met protein expression, as compared to matched 
normal mucosa. The c- Met protein plays a vital homeostatic 
role in epithelial cell function; therefore, the rate of high 
c- met expression (12.25%) by normal mucosa cores (com-
pared to 30.80% in CRC cores) was entirely expected and 
observed in previous immunohistochemical studies of c- Met 
expression.28 Our data support the results of smaller studies; 
Takeuchi et al 29 confirmed c- Met mRNA copies were sig-
nificantly elevated in a small sample of CRC patients relative 
to normal colonic epithelium. Interestingly, their study of 36 
T A B L E  2  Summary of statistical analyses of TMA c- Met expression by IHC score (tumour versus normal tissue)
Tumour Normal Difference
Number of pairs 242
Minimum 0.00 0.00 −14.00
25% Percentile 6.00 2.80 −0.25
Median 12.00 6.00 2.33
75% Percentile 15.00 12.00 7.70
Maximum 15.00 15.00 15.00
Wilcoxon Matched- pairs Signed- Rank Test
P value (two tailed) <.0001 <.0001
95% C.I of median difference 1.00 to 3.50
IQR median difference −0.33 to 7.70
Sum of signed ranks (W) 15 397
Sum of positive rank 22 274
Sum of negative rank −6877
F I G U R E  2  Receiver operating characteristics (ROC) curve and 
area under curve (AUC) for c- Met expression. Sensitivity plotted as a 
function of specificity as percentage at various decision thresholds for 
c- Met as a diagnostic biomarker in colorectal cancer detection
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patients also identified mRNA copy levels correlated with 
primary CRC depth of invasion and lymph node status.
Examination of the diagnostic accuracy of c- Met expres-
sion in CRC tissue samples confirmed that a total c- Met 
expression score of 12 or over, yielded the greatest com-
bined specificity and sensitivity for the detection of CRC, at 
76.19% and 52.29% respectively. The differential expression 
and diagnostic accuracy ROC curve assessment indicates that 
c- Met may have a role in the diagnosis of CRC and could be 
a possible therapeutic target.
Previous studies have confirmed the potential of tissue 
CEA as a diagnostic and surveillance biomarker and the CEA 
receptor protein as an imaging target in CRC.5,27, 30 Tiernan 
et al 5 used a similar scoring method to this study and identi-
fied increased CEA expression in CRC tissue, when compared 
to corresponding normal tissue. Although we found that c- Met 
lacked the diagnostic accuracy of CEA, it outperformed the 
other biomarkers explored in the Tiernan study: epidermal 
growth factor receptor (EGFR), Folate receptor alpha (FRα) 
and tumour- associated glycoprotein 72 (TAG- 72). Formation 
of the proto- oncogene c- Met- HGF ligand complex activates 
several downstream signalling cascades and induces nuclear 
transcription and cellular transformation. This can include 
activation of the RAS protein family.9,11,23 KRAS and NRAS 
mutation status is assessed prior to treatment with anti- EGFR 
agents in CRC. It is possible c- Met interacts with other known 
oncogenic pathways in the development of, and chemotherapy 
resistance seen in CRC Yoon et al confirmed strong correlation 
between c- Met and a related downstream non- receptor tyrosine 
kinase, focal adhesion kinase (FAK) expression H- scores in 
CRC TMA. With the related macrophage- stimulating protein 
receptor (MST1R), a three- protein risk stratification model 
of CRC confirmed high FAK, low c- MET and low MST1R 
protein levels showed the worst progression- free survival and 
a high risk of early progression of disease. In combination, 
c- Met may be beneficial in the diagnosis or prognostication of 
CRC, especially in combination with other novel biomarkers.
5 |  CONCLUSION
Immunohistochemical analysis of c- Met expression in human 
tissue samples showed a significant differential expression 
between matched normal colorectal epithelium and CRC. 
Malignant tissue consistently overexpressed c- Met pro-
tein, relative to normal tissue. Strong c- Met expression only 
yielded a true negative rate of 30.92%. With such a high false 
positive rate, the diagnostic and prognostic utility of c- Met in 
CRC may be limited. Further evaluation of c- Met in conjunc-
tion with other biomarkers is required and may have a prog-
nostic, surveillance or response to treatment predictive role.
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